Treatment of growing teratoma syndrome
DJ Vaughn, K Flaherty, P Lal… - … England Journal of …, 2009 - Mass Medical Soc
DJ Vaughn, K Flaherty, P Lal, M Gallagher, P O'Dwyer, K Wilner, I Chen, G Schwartz
New England Journal of Medicine, 2009•Mass Medical SocTo the Editor: Growing teratoma syndrome consists of an enlarging mature teratoma arising
during or after chemotherapy for a nonseminomatous germ-cell tumor, with normal serum
levels of alpha-fetoprotein and human chorionic gonadotropin. 1 The preferred treatment is
complete surgical resection2 because teratomas are resistant to chemotherapy and
radiation therapy. Although embryonal carcinomas express little or no retinoblastoma
protein (pRB), 3 mature teratomas express high levels of pRB. Normally, cyclin-dependent …
during or after chemotherapy for a nonseminomatous germ-cell tumor, with normal serum
levels of alpha-fetoprotein and human chorionic gonadotropin. 1 The preferred treatment is
complete surgical resection2 because teratomas are resistant to chemotherapy and
radiation therapy. Although embryonal carcinomas express little or no retinoblastoma
protein (pRB), 3 mature teratomas express high levels of pRB. Normally, cyclin-dependent …
To the Editor: Growing teratoma syndrome consists of an enlarging mature teratoma arising during or after chemotherapy for a nonseminomatous germ-cell tumor, with normal serum levels of alpha-fetoprotein and human chorionic gonadotropin.1 The preferred treatment is complete surgical resection2 because teratomas are resistant to chemotherapy and radiation therapy.
Although embryonal carcinomas express little or no retinoblastoma protein (pRB),3 mature teratomas express high levels of pRB. Normally, cyclin-dependent kinase 4/6 (CDK4/6) stimulates cell growth by phosphorylating pRB. The development of selective CDK inhibitors,4 including PD0332991 (Pfizer), which selectively inhibits CDK4/6, suggests a new treatment for growing teratoma syndrome.
We report on . . .
The New England Journal Of Medicine